Your browser doesn't support javascript.
loading
Assessing trends of breast cancer and carcinoma in situ to monitor screening policies in developing settings.
Brito, Érika de Abreu Costa; Lima, Marcela Sampaio; Siqueira, Hianga Fayssa Fernandes; Marques, Adriane Dórea; Moura, Alex Rodrigues; Hora, Evânia Curvelo; Lima, Carlos Anselmo; Santos, Marceli de Oliveira; de Souza, Mirian Carvalho; da Silva, Angela Maria; Brito, Hugo Leite de Farias; Cipolotti, Rosana.
Afiliação
  • Brito ÉAC; Health Sciences Graduate Program, Aracaju, Sergipe, Brazil.
  • Lima MS; University Hospital/EBSERH/Federal University of Sergipe, Aracaju, Sergipe, Brazil.
  • Siqueira HFF; Health Sciences Graduate Program, Aracaju, Sergipe, Brazil.
  • Marques AD; University Hospital/EBSERH/Federal University of Sergipe, Aracaju, Sergipe, Brazil.
  • Moura AR; Health Sciences Graduate Program, Aracaju, Sergipe, Brazil.
  • Hora EC; Health Sciences Graduate Program, Aracaju, Sergipe, Brazil.
  • Lima CA; University Hospital/EBSERH/Federal University of Sergipe, Aracaju, Sergipe, Brazil.
  • Santos MO; Health Sciences Graduate Program, Aracaju, Sergipe, Brazil.
  • de Souza MC; University Hospital/EBSERH/Federal University of Sergipe, Aracaju, Sergipe, Brazil.
  • da Silva AM; Health Sciences Graduate Program, Aracaju, Sergipe, Brazil.
  • Brito HLF; Aracaju Cancer Registry, Aracaju, Sergipe, Brazil. carlos.a.lima@ufs.br.
  • Cipolotti R; Health Sciences Graduate Program, Aracaju, Sergipe, Brazil. carlos.a.lima@ufs.br.
Sci Rep ; 9(1): 14144, 2019 Oct 02.
Article em En | MEDLINE | ID: mdl-31578436
ABSTRACT
There have been arguments about the role of breast cancer screening at the population level, and some points of controversy have arisen, such the establishment of organized screening policies and the age at which to begin screening. The real benefit of screening has been questioned because the results of this practice may increase the diagnosis of indolent lesions without decreasing mortality due to breast cancer. The authors have proposed a study of incidence and mortality trends for breast cancer in a developing setting in Brazil to monitor the effectiveness of the official recommendations that prioritize the age group from 50 to 69 years. The database of the Cancer Registry and the Mortality Information System was used to calculate age-standardized and age-specific rates, which were then used to calculate incidence and mortality trends using the Joinpoint Regression Program. The results showed stability in trends across all ages and age-specific groups in both incidence and mortality. In conclusion, we found that incidence and mortality rates are compatible with those in regions with similar human development indexes, and trends have demonstrated stabilization. Thus, we do not endorse changes in the official recommendations to conduct screening for ages other than 50 to 69 years, nor should policy makers implement organized screening strategies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Detecção Precoce de Câncer / Carcinoma de Mama in situ / Política de Saúde Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: America do sul / Brasil Idioma: En Revista: Sci Rep Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Detecção Precoce de Câncer / Carcinoma de Mama in situ / Política de Saúde Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: America do sul / Brasil Idioma: En Revista: Sci Rep Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil